| Identification | Back Directory | [Name]
5-chloro-N'-[2-(trifluoromethyl)phenyl]sulfonyl-1-benzofuran-2-carbohydrazide | [CAS]
406191-34-2 | [Synonyms]
BCATc Inhibitor 2
5-chloro-N'-[2-(trifluoromethyl)phenyl]sulfonyl-1-benzofuran-2-carbohydrazide
2-Benzofurancarboxylic acid, 5-chloro-, 2-[[2-(trifluoromethyl)phenyl]sulfonyl]hydrazide | [Molecular Formula]
C16H10ClF3N2O4S | [MDL Number]
MFCD34368502 | [MOL File]
406191-34-2.mol | [Molecular Weight]
418.77 |
| Chemical Properties | Back Directory | [storage temp. ]
Store at -20°C, protect from light | [solubility ]
≤10mg/ml in ethanol;20mg/ml in DMSO;25mg/ml in dimethyl formamide | [form ]
crystalline solid | [color ]
White to off-white |
| Hazard Information | Back Directory | [Biological Activity]
bcatc inhibitor 2 is an active and selective inhibitor of cytosolic bcat (bcatc)[1].branched-chain amino acid transferases (bcats) have been implicated in catalyzing reversible transamination of isoleucine, leucine, and valine branched-chain amino acids to their corresponding α-keto acids, generating l-glutamate. it has been identified that there are two forms of bcat in mammals: mitochondrial bcat (bcatm) and cytosolic bcat (bcatc). bcatc is expressed in particular brain region and involved in regulating glutamate synthesis for release during neuronal excitation. thus, bcatc inhibition may be useful for the treatment of neurodegenerative and behavioral disorders involving disturbances of the glutamatergic system [2]. | [in vitro]
bcatc inhibition is likely to be useful for the treatment of neurodegenerative and other neurological disorders involving disturbances of the glutamatergic system. in the hbcatc assays, bcatc inhibitor 2 exhibited an ic50 of 0.8 ± 0.05 μm. in a recombinant rat bcatc assay and a crude rat bcatm assay, the ic50 was 0.2 μm ± 0.02 and 3.0 μm ± 0.5 (n=5), respectively. bcatc inhibitor 2 decreased calcium influx in neuronal cultures with an ic50 of 4.8 ± 1.2 μm (n=4) [1]. | [in vivo]
bcatc inhibitor 2 blocked calcium influx into neuronal cells following inhibition of glutamate uptake, and demonstrated neuroprotective efficacy in vivo. in lewis rats, after treatment with 30 mg/kg bcatc inhibitor 2 (subcutaneous injection), the peak plasma concentration (cmax) reached 8.28 μg/ml at 0.5 h (tmax). the mean plasma exposure (auc) value was 19.9 μg h/ml, and the mean terminal half-life ranged from 12 to 15 h, indicating favorable pk parameters of bcatc inhibitor 2. daily administration of the mitochondrial neurotoxin, 3-nitroproprionic acid (3-np) produced striatal lesions and led to motor deficits. administration of bcatc inhibitor 2 for 9 days almost completely reversed the effects of 3-np [1]. | [storage]
Store at -20°C, protect from light | [References]
[1] hu l y, boxer p a, kesten s r, et al. the design and synthesis of human branched-chain amino acid aminotransferase inhibitors for treatment of neurodegenerative diseases[j]. bioorganic & medicinal chemistry letters, 2006, 16(9): 2337-2340.
[2] brosnan j t, brosnan m e. branched-chain amino acids: enzyme and substrate regulation[j]. the journal of nutrition, 2006, 136(1): 207s-211s. |
|
| Company Name: |
MedChemExpress
|
| Tel: |
021-58955995 |
| Website: |
www.medchemexpress.com |
|